

Drug Policy

Policy:	Fabhalta (iptacopan)	Annual Review Date: 02/20/2024
		Last Revised Date: 02/20/2024

OVERVIEW

Fabhalta, a Factor B inhibitor, is indicated for the treatment of **paroxysmal nocturnal hemoglobinuria** (PNH) in adults.

POLICY STATEMENT

This policy involves the use of Fabhalta. Prior authorization is recommended for pharmacy benefit coverage of Fabhalta. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Fabhalta as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Fabhalta be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Fabhalta is recommended in those who meet the following criteria:

1. **Paroxysmal Nocturnal Hemoglobinuria.** Approve if the patient meets ONE of the following (A or B):
 - A) **Initial therapy.** Approve if the patient meets the following (i, ii, and iii):
 - i. Patient is ≥ 18 years of age; AND
 - ii. Paroxysmal nocturnal hemoglobinuria diagnosis was confirmed by peripheral blood flow cytometry results showing the absence or deficiency of glycosylphosphatidylinositol-anchored proteins on at least two cell lineages; AND
 - iii. Patient has a mean hemoglobin level <10 g/dL; AND
 - iv. Patient has an LDH level of 1.5 times the upper limit of the normal range; AND

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- v. Patient has complete or updated vaccinations for encapsulated bacteria (*Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae*) at least 2 weeks prior to the first dose of Fabhalta; AND
 - vi. The medication is prescribed by or in consultation with a hematologist.
- B) Patient is Currently Receiving Fabhalta.** Approve if the patient meets the following (i, ii, and iii):
- i. Patient is ≥ 18 years of age; AND
 - ii. Patient is continuing to derive benefit from Fabhalta according to the prescriber; AND
Note: Examples of benefit include increase in or stabilization of hemoglobin levels, decreased transfusion requirements or transfusion independence, reductions in hemolysis.
 - iii. The medication is prescribed by or in consultation with a hematologist.

Initial Approval/ Extended Approval.

- A) *Initial Approval: 6 months*
- B) *Extended Approval: 1 year*

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Fabhalta has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

- 1. Concomitant Use with Another Complement Inhibitor.** There is no evidence to support concomitant use of Fabhalta with another another complement inhibitor.
Note: Examples of complement inhibitors are Empaveli (pegcetacoplan subcutaneous injection), Soliris (eculizumab intravenous infusion), and Ultomiris (ravulizumab-cwzy intravenous infusion or subcutaneous injection).
- 2.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational, or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

REFERENCES

1. Fabhalta® capsules [prescribing information]. East Hanover, NJ: Novartis; December 2023.
2. Cançado RD, da Silva Araújo A, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. *Hematol Transfus Cell Ther*. 2021;43:341-348.
3. Shah N, Bhatt H. Paroxysmal Nocturnal Hemoglobinuria. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562292/>. Accessed December 18, 2023.
4. Roth A, Maciejewski J, Nishinura JI, et al. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. *Eur J Haematol*. 2018;101(1):3-11.